Treatment of headaches Flashcards
Biological effects of Brady kinin and Kallidin
autocoids that induce inflammation, pain and vasodilation
Synthesis of kinins
- Kininogens → Kallikrein → Kinins
- Kininogens are precursors of kinins
- Kallikreins are serine proteases that cleave Kininogens into kinins
- High Molecular Weight Kininogen (HMWK) is cleaved by Plasma
Kallikrein into bradykinin - Low Molecular Weight Kininogen (LMWK) is cleaved by Tissue Kallikrein
into kallidin which is then cleaved by an Aminopeptidase into Bradykinin
The plasma kinin forming system
- Autoactivation of factor XII (Hageman Factor) to factor XIIa. Factor XIIa
converts Plasma Prekallikrein to Plasma Kallikrein, Plasma Kallikrein
converts High Molecular Weight Kininogen (HMWK) to Bradykinin. Plasma
Kallikrein activates factor XIIa. This is a positive feedback loop, and the first
step in the intrinsic clotting cascade that enhances Bradykinin synthesis.
The tissue kallikrien-kinin forming system
- Tissue Kallikrein is different than Plasma Kallikrein.
- Tissue Kallikrein converts Low Molecule Weight Kininogen (LMWK) to
Kallidin. Aminopeptidase converts Kallidin to Bradykinin
Metabolism of Kinins
1.Carboxypeptidase N and M (CPN, CPM) (Also known as Kininase I) are
metallopeptidases that cleave Kinins into active kinin metabolites (des-Arg9-
Bradykinin/ des-Arg10-Kallidin).
2. *Angiotensin I-Converting Enzyme (ACE) (also known as Kininase II)
hydrolyzes Bradykinin into inactive products. The cardioprotective and blood
pressure lowering effects of ACE inhibitors (like Captopril) may in part be
due to increases in Bradykinin.
Kinin Receptors
1.B1 and B2 are G protein coupled receptors
2. Native Bradykinin and kallidin activate the B2 receptor.
3. Bradykinin and kinin active metabolites (des-Arg9
-Bradykinin/ des-Arg10-
Kallidin) activate the B1 receptor
4. B2 receptor constitutively expressed in most tissues
5. B1 receptor is induced by tissue damage, inflammation
6. Activation of B receptors stimulates increases in the synthesis of
prostaglandins, NO, EDHF
Drug interactions of Kinins
1.NSAIDS reduce bradykinin and Kallidin-induced increases in PG production
by inhibiting cyclo-oxygenase
2. Corticosteroids reduce bradykinin and Kallidin-induced PG production by
stimulating increases in Lipocortin. Lipocortin is a phospholipase A2
inhibitor
Effects of kinins
1.Pain: kinins can induce the excitation of sensory neurons, which induces the
release of neuropeptides, substance P, neurokinins, and calcitonin gene related
peptide (CGRP). *CGRP is the most potent vasodilator peptide in the
trigeminal system (important for Migraine).
2.Inflammation: Kinins increase permeability of microcirculation which can
promote edema
3. Respiration: Kinins can induce bronchospasms and kinin levels can be
elevated in asthma
4. Cardiovascular: Kinins induce vasodilation and lower BP
Serotonin (5-HT): Biological effects. Platelets, cardiovascular, GI, and CNS
1.Platelets
a) Platelets do not synthesize serotonin but actively take up and store
serotonin. Serotonin release during platelet aggregation promotes platelet
aggregation and vasoconstriction.
2.Cardiovascular
a) Induces vasoconstriction and has positive inotropic and chronotropic
effects on heart
3.GI
a) Enterochromaffin cells release 5-HT in response to vagal stimulation and
stretching with food ingestion. 5-HT will regulate GI motility. 5-HT
producing carcinomas will induce diarrhea and abdominal cramps.
4.CNS
a) 5-HT neurons in raphe nuclei of brain stem and project throughout the
brain and spinal cord.
Synthesis and inactivation of 5-HT
- Serotonin is preferentially inactivated by monoamine oxidase A (MAO-A)
isoform, platelets only express the MAO-B isoform - 5-Hydroxyindoleacetic acid (5-HIAA) is the urinary metabolite of 5-HT
*5-HT1 Receptors
- There are seven 5-HT receptor subtypes some of which have defined
functions including the 5-HT1 family. - The role of 5-HT1B/1D receptors in migraine
a) *5-HT1D induce vasoconstriction of cranial blood vessels. *5-HT1B is an
autoreceptor and its activation inhibits nociceptive trigeminal afferents,
which reduces migraine pain.
Role of 5-HT in Migraine
- Urinary and platelet 5-HT levels decrease during Migraine attacks
- *Triptans are 5-HT1B/1D agonist to treat migraine pain.
- Intravenous infusion of 5-HT aborts spontaneous headache
Migraine Headaches overview and types
1.Afflict over 23 million individuals each year.
Common migraine: Has no aura and has headache.
Classic Migraines: Have aura and HA
Aura
Sensory disturbance in brain prior to headache
• Visual disturbance → scintillating scotoma
• Sensory disturbance → Focal paresthesia
• Motor disturbance → Weakness or paralysis
• Auditory Disturbance → Excessively sensitive to noise or light
Migraine stages
a) Prodome (1 – 2 days prior to attack) GI effects Mood changes
b) Aura (20- 60 min prior to attack)
c) Attack 4hrs – 3 days
d) Postdrome
Characteristics of migraine attack
a) POUND (Pulsating Headache lasting 4-72 hOurs that is Unilateral,
Nauseating and Debilitating)
Pathophysiology of Migraine (Working Model)
a) Genetically susceptible patients
b) Triggers include: stress, certain foods, odors, change in sleep habits
c) Neurovascular headache: a disorder in which neural events results in
further dilation of cranial blood vessels, which in turn, results in pain
and further nerve activation
d) Migraine is not caused by a primary vascular event
e) Migraine is likely caused by brain-stem nuclei that normally
*Drug therapy for Migraine:
Goals
a) Reduce the number of Migraine attacks with Migraine prophylactic drugs
(*if attacks are occurring frequently)
b) Reverse Migraine Attack with Rescue/Abortive Migraine Drugs.
Types of Drugs
a) Prophylactic drugs that reduce the migraine frequency
b) Drugs used to treat Migraine attacks (“rescue or abortive
drugs”) once they occur. These can be further divided into
nonspecific pain-reducing drugs and migraine-specific drugs.
Prophylactic agents: Beta blockers
Propranolol and Atenolol taken orally (FDA approved)
• May take three weeks to be effective
• Relatively well tolerated and effective
*Mechanism by which beta blockers reduce migraine attacks is not
clear. Hyperfunctioning of the sympathetic nervous system has been
suspected in patients with migraines.
• Side effects are reduced energy, tiredness
• Contraindicated in patients with asthma
Prophylactic agents: Tricyclic Antidepressants
Amitriptyline and Nortriptyline are taken orally
• The precise mechanism of the anti-migraine effects of tricyclic
antidepressants is not clear, however, could be attributed to
inhibition of serotonin reuptake.
• *Side effects limit use and include significant antimuscarinic
properties, weight gain and tiredness.
Prophylactic agents: Anticonvulsants
• Valproic acid, Topiramate, Gabapentin & Levetiracetam taken
orally
• Effective in some patients. Mechanisms of anti-migraine activity not
clear. Increases in gamma-aminobutyric acid (GABA) signaling
could play a role.
• Valproic Acid is contraindicated in pregnancy because of
teratogenicity. Side effects include drowsiness, anorexia, nausea,
ataxia, alopecia, tremor as well as liver toxicity.
• Used especially in migraine patients with epilepsy or anxiety
disorders
Prophylactic agents: Calcium channel blockers
Verapamil
• Antihypertensive drug that reduces the incidence of migraine
through mechanisms that are not clear
• Side effects include negative inotropic cardiac effects, hypotension
Prophylactic agents: Cyproheptadine:
Potent antagonist of histamine, acetylcholine, and serotonin
• Used for seasonal allergy and pruritus from histamine release
• Cyproheptadine has proven effective in the prophylaxis of migraine
headache
• Side effects include high incidence of CNS depression and
sleepiness